See more : Tradehold Limited (TDH.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Ultragenyx Pharmaceutical Inc. (RARE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ultragenyx Pharmaceutical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tricida, Inc. (TCDA) Income Statement Analysis – Financial Results
- TORQ Inc. (8077.T) Income Statement Analysis – Financial Results
- M2i Global, Inc. (MTWO) Income Statement Analysis – Financial Results
- Dongwu Cement International Limited (0695.HK) Income Statement Analysis – Financial Results
- Shoucheng Holdings Limited (0697.HK) Income Statement Analysis – Financial Results
Ultragenyx Pharmaceutical Inc. (RARE)
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 434.25M | 363.33M | 351.41M | 271.03M | 103.71M | 51.50M | 2.61M | 133.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 45.21M | 28.32M | 16.01M | 6.13M | 9.01M | 1.15M | 1.00K | 183.20M | 1.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 389.04M | 335.01M | 335.40M | 264.90M | 94.71M | 50.35M | 2.61M | -183.07M | -1.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 89.59% | 92.21% | 95.44% | 97.74% | 91.31% | 97.77% | 99.96% | -137,647.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 648.45M | 705.79M | 497.15M | 412.08M | 357.36M | 294.00M | 231.64M | 183.20M | 114.74M | 45.97M | 27.83M | 12.64M | 4.72M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.72M | 99.91M | 64.94M | 33.00M | 10.81M | 4.45M | 3.34M | 1.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 309.80M | 278.14M | 219.98M | 182.93M | 161.52M | 127.72M | 99.91M | 64.94M | 33.00M | 10.81M | 4.45M | 3.34M | 1.84M |
| Other Expenses | 0.00 | 9.51M | 241.00K | 7.65M | 12.45M | 3.95M | 10.60M | 2.17M | -200.00K | -3.02M | -3.01M | -350.00K | -22.00K |
| Operating Expenses | 958.25M | 983.93M | 717.14M | 595.02M | 518.88M | 421.72M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.99M | 6.56M |
| Cost & Expenses | 1.00B | 1.01B | 733.14M | 601.15M | 527.89M | 422.87M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.99M | 6.56M |
| Interest Income | 26.69M | 11.07M | 1.93M | 7.04M | 13.24M | 9.54M | 4.07M | 3.79M | 2.32M | 608.00K | 216.00K | 1.00K | 4.00K |
| Interest Expense | 66.00M | 43.02M | 29.42M | 33.29M | 1.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 270.00K |
| Depreciation & Amortization | 26.01M | 18.20M | 13.24M | 12.26M | 8.54M | 19.54M | 5.83M | 3.42M | 1.38M | 684.00K | 444.00K | 313.00K | 34.00K |
| EBITDA | -516.45M | -640.51M | -410.32M | -139.81M | -389.77M | -177.56M | -312.51M | -244.58M | -146.35M | -56.09M | -34.63M | -16.02M | -6.55M |
| EBITDA Ratio | -118.93% | -175.99% | -108.56% | -118.98% | -396.98% | -1,051.94% | -12,593.49% | -186,471.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -569.21M | -648.92M | -381.74M | -330.12M | -424.17M | -371.37M | -328.94M | -248.01M | -147.74M | -56.78M | -32.28M | -15.99M | -6.56M |
| Operating Income Ratio | -131.08% | -178.60% | -108.63% | -121.80% | -408.98% | -721.18% | -12,593.49% | -186,471.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -39.26M | -52.81M | -71.24M | 144.76M | 24.73M | 174.28M | 10.60M | 2.17M | 2.12M | -3.02M | -2.79M | -349.00K | -288.00K |
| Income Before Tax | -608.46M | -701.73M | -452.98M | -185.36M | -399.44M | -197.10M | -318.34M | -245.84M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
| Income Before Tax Ratio | -140.12% | -193.14% | -128.91% | -68.39% | -385.14% | -382.75% | -12,187.52% | -184,841.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.83M | 5.70M | 1.04M | 1.21M | 3.28M | 514.00K | -16.20M | 35.00K | -2.32M | -684.00K | -3.01M | -350.00K | 248.00K |
| Net Income | -606.64M | -707.42M | -454.03M | -186.57M | -402.73M | -197.61M | -302.14M | -245.87M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
| Net Income Ratio | -139.70% | -194.71% | -129.20% | -68.84% | -388.31% | -383.75% | -11,567.34% | -184,867.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.30 |
| EPS Diluted | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.30 |
| Weighted Avg Shares Out | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
| Weighted Avg Shares Out (Dil) | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
Ultragenyx (RARE) Posts New Data From Bone Disease Study
Source: https://incomestatements.info
Category: Stock Reports